ArticleFrontiers in immunology2026

Adverse event reporting patterns of rituximab and obinutuzumab in B-cell non-Hodgkin lymphoma: a FAERS pharmacovigilance study.

Weihao Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.